Search
Hydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigationalMagnesium citrate is a low volume and osmotic cathartic agent. … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Mixtures: Calcium Magnesium Plus Vitamin D Liquid, Calcium and Magnesium Citrate With Vitamin DButamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawnButamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942]
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19344ApprovedInvestigationalStreptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus … pneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawnIpecac is obtained from the plant _Cephaelis ipecacuanha_ and contains a number of emetic alkaloids including emetine and cephaeline. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency
Categories: Complex MixturesProtirelin
go.drugbank.com/drugs/DB09421ApprovedAlthough not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary … It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary.
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.
Mixtures: PAMOATO DE PIRANTEL/PAMOATO DE OXANTEL SUSPENSION, PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN.